IDF23-0498 Subgroup analysis of Phase 3 study of dapagliflozin, glimepiride and metformin ER FDC in T2DM patients with HbA1c 9%–11%
2024; Elsevier BV; Volume: 209; Linguagem: Inglês
10.1016/j.diabres.2024.111265
ISSN1872-8227
AutoresRakesh Sahay, Dr Amar Gangwani, Mini P. Singh, Sandeep K. Gupta, Mandodari Rajurkar, Soma Saha, Deepak Y. Patil, P. Ghadge, Lalit Lakhwani, Suyog Mehta, Shruti Joglekar,
Tópico(s)Antiplatelet Therapy and Cardiovascular Diseases
Referência(s)